Abeona Therapeutics (ABEO) Operating Expenses (2011 - 2026)

Abeona Therapeutics' Operating Expenses history runs 16 years deep, the most recent figure standing at $31.8 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 60.96% year-over-year to $31.8 million; the TTM figure through Mar 2026 stood at $107.3 million (up 54.14% YoY), while the FY2025 annual figure was $95.3 million, up 48.37% from the prior year.
• Operating Expenses for Q1 2026 stood at $31.8 million, up from $28.3 million in the prior quarter.
• The five-year high for Operating Expenses was $31.8 million in Q1 2026, with the low at $9.0 million in Q2 2022.
• The 5-year median for Operating Expenses is $15.3 million (2024), against an average of $17.3 million.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses sank 73.81% in 2022, then surged 69.93% in 2025.
• Abeona Therapeutics' Operating Expenses stood at $13.0 million in 2022, then increased by 1.58% to $13.2 million in 2023, then advanced by 26.22% to $16.7 million in 2024, then soared by 69.93% to $28.3 million in 2025, then grew by 12.08% to $31.8 million in 2026.
• Business Quant data shows ABEO's Operating Expenses at $31.8 million in Q1 2026, $28.3 million in Q4 2025, and $24.0 million in Q3 2025.